肾透明细胞癌
磷酸化
基因敲除
蛋白激酶B
癌症研究
细胞生长
生物
PI3K/AKT/mTOR通路
抑制器
肾细胞癌
细胞
细胞周期
细胞生物学
信号转导
细胞凋亡
内科学
基因
医学
生物化学
作者
Jiancheng Zhou,Zhuo Deng,Xinqi Pei,Jiawei Lai,Kaijie Wu,Weixing Qu
标识
DOI:10.1007/s10142-023-01255-1
摘要
Abstract Renal cell carcinoma (RCC) is the most lethal of the urologic malignancies. We previously discovered that DAB2IP, a novel Ras-GTPase-activating protein, was frequently epigenetically silenced in RCC, and DAB2IP loss was correlated with the overall survival of RCC patients. In this study, we determined the biological functions of DAB2IP in RCC and its potential mechanisms of action. Correlations between DAB2IP expression level and RCC tumor size and patient survival were analyzed, and the results showed that RCC patients with high DAB2IP mRNA level exhibited smaller tumor size and better survival than the patients with low DAB2IP. Compared to control cells, DAB2IP knockdown (KD) cells showed enhanced cell proliferation, promoted G1/S phase cell cycle progression and decreased expression of p27. Mechanism studies demonstrated that loss of DAB2IP promoted p27 protein phosphorylation, cytosolic sequestration and subsequently ubiquitination-mediated degradation in RCC cells. Further studies confirmed that the proline-rich domain in C terminal (CPR) of DAB2IP suppressed AKT phosphorylation and induced p27 phosphorylation on S10. Hence, DAB2IP is essential for p27 protein stabilization in RCC, which is at less partly mediated by PI3K/AKT signaling pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI